ReviewInternational journal of molecular sciences2023
Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- Molecular Targets in Modern Cosmetic Science.Molecules (Basel, Switzerland) · 2026Review
- Recent Developments in the Diagnosis and Treatment of Disseminated and Rare Melanoma with Radiotheranostics.ACS pharmacology & translational science · 2026Review
- Phytochemical-based nanomedicine as a promising therapeutic strategy for erectile dysfunction.Asian journal of andrology · 2026Review
- Metapanax delavayi extract as a neurocutaneous modulator via CRHR1/POMC/MC1R signaling.Scientific reports · 2026Article
- Blocking ASIP to Protect MC1R Signaling and Mitigate Melanoma Risk: An In Silico Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- The melanocortin receptors as targets for general obesity: contextualizing clinical failures and analyzing future perspectives.Frontiers in endocrinology · 2026Review
- NDP-MSH rescues LPS-induced neuroinflammation, synaptic deficits, and depressive-like behaviors in mice: involvement of MC1R-cAMP/PKA signaling.Frontiers in pharmacology · 2026Article
- Article
- The Novel Achievements in Oncological Metabolic Radio-Therapy: Isotope Technologies, Targeted Theranostics, Translational Oncology Research.Medical sciences (Basel, Switzerland) · 2025Review
- Disruption of mc1r Disturbs Skin Pigmentation in Xenopus tropicalis.Pigment cell & melanoma research · 2025Article
- Unraveling the genetic diversity and adaptive traits of laboratory pig breeds within the perspective of whole - genome resequencing.BMC genomics · 2025Article
- Biased agonism of G protein-coupled receptors as a novel strategy for osteoarthritis therapy.Bone research · 2025Review
- Antimicrobial Neuropeptides and Their Receptors: Immunoregulator and Therapeutic Targets for Immune Disorders.Molecules (Basel, Switzerland) · 2025Review
- Preparation and Characterization of Universal Liquid Proliposomes Encapsulating Water-soluble Efficacious Substances.Current pharmaceutical biotechnology · 2025Article
- Future Directions in Anxiolytic Therapy: A Comprehensive Review of Novel Targets and Strategies.Current neurovascular research · 2025Review
- The melanocortin receptor genes are linked to and associated with the risk of polycystic ovary syndrome in Italian families.Journal of ovarian research · 2024Article
- Integrin Targeting and Beyond: Enhancing Cancer Treatment with Dual-Targeting RGD (Arginine-Glycine-Aspartate) Strategies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Decoding the impact of ageing and environment stressors on skin cell communication.Biogerontology · 2024Review
- Alpha-melanocyte-stimulating hormone contributes to an anti-inflammatory response to lipopolysaccharide.Molecular metabolism · 2024Article
- Melanocortin Derivatives Induced Vascularization and Neuroglial Proliferation in the Rat Brain under Conditions of Cerebral Ischemia.Current issues in molecular biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Melanocortins play crucial roles in regulating the stress response, inflammation, and skin pigmentation. In this review, we focus on the melanocortin 1 receptor (MC1R), a G protein-coupled receptor primarily known for regulating skin pigmentation and exhibiting anti-inflammatory effects. First, we provide an overview of the structure, signaling pathways, and related diseases of MC1R. Next, we discuss the potential therapeutic use of synthetic peptides and small molecule modulators of MC1R, highlighting the development of various drugs that enhance stability through amino acid sequence modifications and small molecule drugs to overcome limitations associated with peptide characteristics. Notably, MC1R-targeted drugs have applications beyond skin pigmentation-related diseases, which predominantly affect MC1R in melanocytes. These drugs can also be useful in treating inflammatory diseases with MC1R expression present in various cells. Our review underscores the potential of MC1R-targeted drugs to treat a wide range of diseases and encourages further research in this area.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.